Anixa Biosciences, Inc. (ANIX)
3.48
-0.12
(-3.33%)
USD |
NASDAQ |
Aug 28, 16:00
3.59
+0.11
(+3.16%)
After-Hours: 20:00
Anixa Biosciences Free Cash Flow : -7.117M for April 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| April 30, 2026 | -7.117M |
| January 31, 2026 | -6.879M |
| October 31, 2025 | -7.173M |
| July 31, 2025 | -6.845M |
| April 30, 2025 | -7.977M |
| January 31, 2025 | -7.93M |
| October 31, 2024 | -7.335M |
| July 31, 2024 | -8.377M |
| April 30, 2024 | -7.179M |
| January 31, 2024 | -6.53M |
| October 31, 2023 | -6.209M |
| July 31, 2023 | -5.833M |
| April 30, 2023 | -5.784M |
| January 31, 2023 | -7.283M |
| October 31, 2022 | -6.492M |
| July 31, 2022 | -5.943M |
| April 30, 2022 | -6.028M |
| January 31, 2022 | -4.963M |
| October 31, 2021 | -4.937M |
| July 31, 2021 | -5.307M |
| April 30, 2021 | -5.117M |
| January 31, 2021 | -5.432M |
| October 31, 2020 | -6.192M |
| July 31, 2020 | -6.114M |
| April 30, 2020 | -5.464M |
| Date | Value |
|---|---|
| January 31, 2020 | -5.518M |
| October 31, 2019 | -4.917M |
| July 31, 2019 | -4.607M |
| April 30, 2019 | -5.157M |
| January 31, 2019 | -4.299M |
| October 31, 2018 | -4.312M |
| July 31, 2018 | -4.037M |
| April 30, 2018 | -4.101M |
| January 31, 2018 | -4.425M |
| October 31, 2017 | -3.827M |
| July 31, 2017 | -3.759M |
| April 30, 2017 | -3.324M |
| January 31, 2017 | -3.634M |
| October 31, 2016 | -3.528M |
| July 31, 2016 | -3.645M |
| April 30, 2016 | -3.536M |
| January 31, 2016 | -3.928M |
| October 31, 2015 | 1.309M |
| July 31, 2015 | 1.748M |
| April 30, 2015 | 2.120M |
| January 31, 2015 | 3.391M |
| October 31, 2014 | -2.379M |
| July 31, 2014 | -2.560M |
| April 30, 2014 | -3.063M |
| January 31, 2014 | -3.466M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Sarepta Therapeutics, Inc. | 58.34M |
| Vicapsys Life Sciences, Inc. | -0.1292M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -1.741M |
| Cash from Investing (Quarterly) | 0.422M |
| Cash from Financing (Quarterly) | 1.249M |
| Free Cash Flow Per Share (Quarterly) | -0.0518 |
| Free Cash Flow to Equity (Quarterly) | -1.732M |
| Free Cash Flow to Firm (Quarterly) | -1.741M |
| Free Cash Flow Yield | -6.18% |